GSK3B and Alzheimer disease: Treatment with AST and AST-LI reversed these alterations, restoring BDNF levels (Fig. 9) and synaptic plasticity, further emphasizing the therapeutic and functional linking of SIRT-1/BDNF/miRNA-134/GSK-3β signaling in AD management.